Please use this identifier to cite or link to this item:
Title: Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Authors: Perez-Molina, J A
Rubio, R
Rivero, A
Pasquau, J
Suárez-Lozano, I
Riera, M
Estébanez, M
Palacios, R
Sanz-Moreno, J
Troya, J
Mariño, A
Antela, A
Navarro, J
Esteban, H
Moreno, S
GeSIDA 7011 Study Group
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Anti-HIV Agents
Antiretroviral Therapy, Highly Active
Maintenance Chemotherapy
Middle Aged
Treatment Outcome
Viral Load
Young Adult
Issue Date: 13-Sep-2016
Abstract: We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r + 3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r + 2NUCs) at 96 weeks of follow-up. SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patients. Hepatitis B virus surface antigen-negative subjects with no previous treatment failure/resistance mutations and HIV-1-RNA Some 286 patients were analysed. At week 96, 74.4% had HIV-1-RNA The long-term results of switching to ATV/r + 3TC show that this strategy is effective, safe and non-inferior to ATV + 2NUCs in virologically suppressed HIV-infected patients.
metadata.dc.identifier.doi: 10.1093/jac/dkw379
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.